Opinion

Video

Monitoring Treatment Response

Author(s):

Brian Helfand, MD, PhD,Gordon A. Brown, DO

A panel of experts on prostate cancer share strategies for monitoring patients and discuss whether to use PSMA to monitor treatment response.

Current Time 0:00
Duration 5:47
Loaded: 2.83%
Stream Type LIVE
Remaining Time 5:47
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
    • en (Main), selected

    Newsletter

    Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

    Subscribe Now!
    Related Videos
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Laura Davis, MD, on persistent poverty and early onset prostate cancer
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Alicia Morgans, MD, highlights the phase 3 ARASTEP trial
    Ruben Olivares, MD, answers a question during a Zoom video interview
    Ruben Olivares, MD, discusses HIFU and remote prostate cancer care
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Mitchell Huang, MD, on the cost-effectiveness of transperineal vs transrectal prostate biopsy
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Alicia Morgans, MD, on QOL outcomes with darolutamide plus ADT in mHSPC
    Blur image of hospital corridor | Image Credit: © zephyr_p - stock.adobe.com
    Post-RP incontinence: Low procedure rates examined
    Bashir Al Hussein Al Awamlh, MD, MPH, answers a question during a Zoom video interview
    Data link incontinence severity to post-radical prostatectomy care
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Jim Hu, MD, on upgrading of GG1 prostate cancer at radical prostatectomy
    Man talking with a doctor | Image Credit: © Chinnapong - stock.adobe.com
    Expert discusses differentiating prostate cancer from age-related issues
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Murilo De Almeida Luz, MD, on PSA and ALP changes with enzalutamide/radium-223
    Related Content
    Patient talking with a doctor | Image Credit: © Pcess609 - stock.adobe.com
    July 10th 2025

    FDA grants breakthrough device designation for ArteraAI Prostate tool

    Benjamin P. Saylor Hannah Clarke
    “This designation is a powerful validation of our software's potential to transform how we treat cancer,” said Andre Esteva, CEO of Artera.
    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025 | Credit: Urology Times
    April 27th 2025

    Pearls & Perspectives: Helen Bernie, DO, MPH, at AUA 2025

    Amy M. Pearlman, MD Helen L. Bernie, DO, MPH
    Helen Bernie, DO, MPH, joins the show to discuss data from her Indiana University team from the floor at AUA 2025.
    FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC
    July 9th 2025

    FDA grants fast track designation to TRE-515 with 177Lu-PSMA-617 for mCRPC

    Benjamin P. Saylor Hannah Clarke
    The investigational treatment is being evaluated in phase 1 clinical trials for solid tumors.
    Dr. Murphy on increasing diversity in cancer clinical trials
    February 29th 2024

    Dr. Murphy on increasing diversity in cancer clinical trials

    Urology Times staff
    In this podcast episode, Adam B. Murphy, MD, MBA, MSCI, discusses the need to increase diversity in clinical trials, specifically focusing on studies in prostate cancer.
    Expanded indication sought for niraparib plus AAP in Europe
    July 7th 2025

    Expanded indication sought for niraparib plus AAP in Europe

    Hannah Clarke
    The application is supported by data from the phase 3 AMPLITUDE trial.
    Regulatory recap: FDA approvals in urology from the first half of 2025
    July 4th 2025

    Regulatory recap: FDA approvals in urology from the first half of 2025

    Hannah Clarke
    Take a look through all the regulatory milestones in urology from the first half of the 2025.
    © 2025 MJH Life Sciences

    All rights reserved.